• Explore /
  • Poster
  • / Updated results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.

Updated results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.

Abstract Poster

Authors

null

Ning Li

The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China;

Ning Li , Tao Wu , Yong-Gui Hong , Yanzhen Guo , Yufeng Cheng , Baosheng Li , Junsheng Wang , Suxia Luo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04063683

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 376)

DOI

10.1200/JCO.2023.41.4_suppl.376

Abstract #

376

Poster Bd #

F17

Abstract Disclosures

Similar Posters

First Author: Junsheng Wang

First Author: Junsheng Wang

First Author: Shui-Ling Jin

First Author: Jin Yan